Compare AFBI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFBI | SERA |
|---|---|---|
| Founded | 1928 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.6M | 130.5M |
| IPO Year | N/A | 2021 |
| Metric | AFBI | SERA |
|---|---|---|
| Price | $21.12 | $3.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.3K | ★ 56.9K |
| Earning Date | 01-30-2026 | 11-13-2025 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | ★ 37.47 | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $31,784,000.00 | $95,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $347.37 |
| P/E Ratio | $18.08 | ★ N/A |
| Revenue Growth | ★ 3.87 | 1.06 |
| 52 Week Low | $17.00 | $1.37 |
| 52 Week High | $22.50 | $8.73 |
| Indicator | AFBI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 66.99 | 60.36 |
| Support Level | $20.25 | $3.38 |
| Resistance Level | $22.25 | $3.66 |
| Average True Range (ATR) | 0.28 | 0.23 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 49.78 | 85.20 |
Affinity Bancshares Inc is a holding company of Affinity Bank, a federally chartered stock savings bank that offers a variety of deposit accounts, including checking accounts, savings accounts, and certificate of deposit accounts. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate loans, commercial and industrial loans, residential real estate loans, construction and land loans, and consumer loans. It also invests in securities, which consist of mortgage-backed securities and obligations issued by United States government-sponsored enterprises and Federal Home Loan Bank stock.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.